Skip to main content

Neuro-Behçet’s disease in childhood: A focus on the neuro-ophthalmological features


Neuro-Behçet’s disease (NBD) involves the central nervous system; peripheral nervous system involvement is not often reported. NBD is quite common in adult patients and occurs rarely during childhood and adolescence. Young patients may share symptoms and signs of NBD with other neuro-ophthalmological disorders (e.g. idiopathic intracranial hypertension); thus, making the differential diagnosis difficult. Neuroimaging is mandatory and necessary for a correct NBD diagnosis but in children radiological examinations are often difficult to perform without sedation. From 1971 to 2011, 130 patients aged ≤16 years have been reported with NBD, according to retrospective surveys, case series, and case reports. The origin of the reported cases met the well-known geographical distribution of Behçet’s disease (BD); the mean age at presentation of neurological findings was 11.8 years, with male gender prevalence (ratio, 2.9:1). We considered in detail the neuro-ophthalmological features of the 53 cases whose neuroimaging alterations were described with an assigned radiological pattern of the disease (parenchymal: 14 cases, non-parechymal: 35 cases, and mixed: 4 cases). In 19/53 patients (36%), neuro-ophthalmological symptoms anticipated any pathognomonic sign for a BD diagnosis, or only occasional aphtae were recalled by the patients. Family history was positive in 17% of subjects. Headache was reported in 75% of the patients; in those presenting with cerebral vascular involvement, headache was combined to other symptoms of intracranial hypertension. Papilledema was the most frequently reported ophthalmological finding, followed by posterior uveitis. Treatment consisted of systemic steroids in 93% of patients, often combined with other immunosuppressive drugs (especially colchicine and azathioprine). Clinical recovery or improvement was documented in the large majority of patients. Nine subjects had definitive alterations, and one died. Based on our review and personal experience, a delayed diagnosis, and the consequently delayed immunosuppressive treatment, may favour permanent sequelae, in particular, optic atrophy.


Behçet’s disease (BD) is an inflammatory, multisystem disease named after the Turkish dermatologist who first correlated the three characteristic findings, including recurrent oral and genital aphtae, and uveitis [1]. The currently addressed diagnostic criteria were defined in 1990 by the International Society for Behçet’s Disease [2]. However, these criteria make no specific reference to central nervous system (CNS) involvement. This condition, usually called neuro-Behçet’s disease (NBD), has variable prevalence depending on the series, but can represent 9–10% of affected patients [3]. Cerebral computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), and functional neuroimaging such as single-photon emission computed tomography (SPECT) have become the reference radiological tools for diagnosis and have proven particularly useful in ruling out differential diagnoses (e.g., idiopathic intracranial hypertension, IIH). The radiological pattern of the disease has been divided into two major forms: 1) the parenchymal form, which is clinically subdivided into acute and chronic progressive; and 2) the non-parenchymal (or vascular) form [4]. In the parenchymal type, the acute pattern is characterised by acute meningoencephalitis with or without focal lesions; the chronic progressive pattern is characterised by slowly progressive central and peripheral alterations such as dementia, ataxia, or dysarthria, along with a persistently marked elevation of interleukin-6 in the cerebrospinal fluid [57]. In the non-parenchymal type, parenchymal damage is possible, but occurs secondary to pathological processes localised in the large venous or, more rarely, arterial cerebral vessels [8, 9]. The concomitance of parenchymal and vascular involvement has been classified in some studies as mixed parenchymal and non-parenchymal [3, 10].

Unlike younger subjects, adult patients often develop neurological involvement after some non-neurological manifestations of BD [11], which greatly favours a correct diagnosis and early treatment. Although not predominant, neuro-ophthalmological findings in BD have been reported for a long time in children, and optic atrophy is a major consequence [1214]. However, the prevalence of such complications is difficult to ascertain from available reports, mainly because of the limited number of patients and the lack of clear details about respective neurological findings [3]. An extensive review of the literature on pediatric NBD, focusing on the neuro-ophthalmological features in cases with a definitive radiological diagnosis, is presented and discussed.


This review was designed to examine all reports concerning subjects aged ≤16 years having BD and presenting with any related CNS involvement. A diagnosis of BD was considered if it matched the international classification criteria (Japanese or European) [2, 15]. Other criteria were accepted when they were the standard by the date of publication or when they were based on distinctive neuroimaging.

We searched MEDLINE (October 1971–December 2011) and EMBASE (January 1980–December 2011) singly and in combination using the following key words: Behçet, Behçet’s disease, neuro-Behçet, neurology, imaging, venous thrombosis, central nervous system, optic nerve, paediatric, juvenile, and young. Articles written in English, French, German, and Italian were fully reviewed. Other languages were reviewed from the Abstract. The Reference sections of the articles were reviewed for any article that had been missed in the electronic search.

The primary outcome of this review was to evaluate the neurological and ophthalmological features of the disease in young patients. Secondary outcomes that were evaluated were other aspects of the disease, in particular: time of presentation of neuro-ophthalmological findings, family history, drugs used for treatment, and prognosis. Considering the difficulty of the differential diagnosis and the problems related to classifying NBD, we decided to limit a detailed analysis of the above mentioned outcomes to those cases with a definitive diagnosis based on neuroimaging. A concise overview of the same parameters was however performed in cases for whom a precise radiological characterisation was not reported. The demographic data were considered for all patients described in the literature.


Source literature

In total, 38 articles have reported 130 patients within the considered range of age who were affected by BD with neurological involvement (excluding the cases with isolated headache) [12, 14, 1651]. Among these articles, two were nationwide retrospective surveys [31, 32], and five studies described eligible subjects selected from large retrospective chart reviews [14, 30, 43, 48, 49]. In one study, new examinations were performed in a small cohort of subjects [34]. The remaining studies were single-case reports or case series.


The demographics of all described subjects are summarized in Table 1. Sixty-nine patients (53%) originated from the so-called “silk road” stretching from Morocco to Japan [14, 17, 18, 28, 3033, 35, 3742, 44, 4850]. The large majority of these subjects (64/69 subjects) were from Western Asia, and only five were from other regions along this historical route [31, 41]. In addition to the large number of Asian subjects, 24 patients (26%) were from Europe: 14 were French [12, 32, 36, 48], eight were Italian [29, 34, 46, 47], and two were from the UK [22, 43]. The remaining geographical areas had minor prevalence (see Table 1). [16, 1921, 2327, 37, 45] The origins of 25 patients were not specified. Gender was reported in 71/130 subjects, with 53 males (75%) and 18 females. The mean age calculated from the available data was 11.8 years.

Table 1 Demographics of patients with juvenile Neuro-Behçet disease reported in the literature from 1971 to 2011 (only when specified)

Clinical evidences

We considered that a definitive diagnostic characterisation was achieved in the fifty-three subjects whose neuroimaging (MRI, and/or MRV, and/or CT, and/or SPECT) was clearly reported. We tabled the neuro-ophthalmological features for each of these subjects [14, 26, 27, 3338, 4042, 4448, 50]. Data referring to the 14 cases having the parenchymal form are detailed in Table 2. The 35 cases presenting with the non-parenchymal form are described in Table 3, and the four cases with mixed parenchymal and non-parenchymal forms are shown in Table 4. The series published by Koné-Paut and co-authors in 1998, 2002, and 2011 [32, 51, 52] were excluded from the tables because the patients with a neurological pattern were described as miscellaneous. The series by Uluduz and co-workers was included as a single comprehensive item, because the authors did not detail symptoms of distinct patients.

Table 2 Ocular and neurological characteristics of patients with juvenile parenchymal Neuro-Behçet reported in the literature from 1971 to 2011
Table 3 Ocular and neurological characteristics of patients with juvenile non-parenchymal Neuro-Behçet reported in the literature from 1971 to 2011
Table 4 Ocular and neurological characteristics of patients with juvenile mixed parenchymal and non-parenchymal Neuro-Behçet reported in the literature from 1971 to 2011

In 12/53 patients (23%), neurological and/or ophthalmological symptoms anticipated any other major or minor criteria for a diagnosis of BD [14, 26, 27, 33, 34, 36, 40, 44, 47, 48], and in seven additional patients, only previous oral/genital aphtae were recalled by the patient [14, 35, 38, 41, 42, 45, 50]. NBD was diagnosed at presentation in 13 subjects [14, 36, 37], and before neurological involvement in 21 patients [14, 46, 48]. Nine patients had a positive family history of BD (17%) [14, 35, 44, 48], 30 patients had a negative family history [14, 26, 42, 48], and information was not specified in 14 patients [27, 34, 3638, 40, 41, 4547].

Forty patients (75%) complained of headache (persistent or recurrent). Related CNS involvement was specified in only 16/40 (40%) patients. Eleven of these 16 subjects (69%) had cerebral vascular involvement (thrombosis, infarct, haemorrhage, inflammation) with headache, nausea, vomiting, and/or papilledema. Nine of the 14 patients (64%) with parenchymal NBD had symptoms and signs suggestive of cerebral hemispheric involvement, including encephalomyelitis, hemiparesis, seizure, and mental changes. Two patients (14%) were reported as having the brainstem form combined with meningitis. Other syndromes were reported in four subjects: spinal cord involvement in two cases (14%), and pure acute meningeal syndrome in two cases. Detailed ophthalmological findings were clearly related to the corresponding radiological pattern in only 27 records (51%). The most frequently reported sign (14 subjects, 52%) was optic nerve head involvement, which occurred in the form of papilledema in 12 cases (86%), unilateral neuritis in one case (7%), and bilateral papillitis in another subject. Ocular inflammation was reported in 11 subjects (41%), selectively affecting the posterior pole of the eye (retinal vasculitis) in most cases (nine subjects, 82%). A disturbance of ocular motility (diplopia, nystagmus) was documented in eight subjects (30%) distributed over the three forms of the disease, and two more patients (7%) presented with ptosis. Blurry vision was a commonly reported generic symptom.

Treatment and prognosis

An immunosuppressive therapy was reported in all patients. Different immunosuppressive drugs, mostly in combination, were used for treatment. Details on the therapy were available for 28 subjects (53%): steroids (oral and/or intravenous) were the most administered treatment (26 patients, 93%); [26, 27, 3338, 4042, 4548, 50] followed by colchicine (14 patients, 52%); [35, 40, 42, 45, 48, 50] azathioprine (12 patients, 44%); [34, 42, 4648, 50] cyclosporine (five patients, 19%); [34, 37, 41, 46, 48] methotrexate (four patients, 15%); [36, 41, 45] anti-tumour necrosis factor drugs (three patients, 11%); [4547] cyclophosphamide (two patients, 7%); [46, 48] and chlorambucil (one patient, 4%) [27]. Adjunctive treatments consisted of anti-seizure medications, anti-coagulants, aspirin, and acetazolamide [27, 3437, 42, 44, 48, 50]. Seven patients had relapses of the neuro-ophthalmological symptoms and required renewal of therapy or implementation of ongoing immunosuppressive treatment. Nine subjects (17%) had definitive sequelae [14, 48]. Motor and sensory sequelae, visual disturbances (blurry vision, low visual acuity, unilateral or bilateral blindness due to optic atrophy), personality changes with behaviour abnormalities, and cognitive difficulties were observed. One patient presenting with the vascular form died as a consequence of the rupture of a cerebral aneurysm (presence of multiple aneurysms) [27]. In the large majority of the patients, a complete recovery or significant improvement was reported [14, 26, 3338, 4042, 4448, 50].

In the remaining seventy-seven subjects described in the literature, neuroimaging was not available, or not clearly described (except for 2 patients with only an initial normal neuro-radiological examination reported) [12, 1625, 2832, 39, 43, 49, 51]. A distinction between parenchimal and non-parenchiaml form was conceivable for 24 patients: 19 cases (79%) presenting the parenchimal, and 5 cases presenting the non-parenchimal pattern. Ocular involvement was reported in 60 subjects (78%) but detailed in only 19 records. Among these, diplopia, cranial nerve palsies, and uveitis were the findings most frequently observed. Optic atrophy was reported in 5 patients. Concerning functional prognosis, 57% of patients showed an improvement after immunosuppressive therapy; the remaining cases (43%) had less satisfactory course due to poor responsiveness to treatment, frequent relapses, or optic atrophy.


BD typically affects young adults and is less common in children; this may explain why the International Study Group Criteria apply mainly to adult patient [2, 53]. Furthermore, these criteria make no specific reference to CNS involvement. In the literature, the terms “paediatric” and “juvenile” are often used interchangeably. Koné-Paut [54] used the term “paediatric” for complete forms in paediatric-aged patients, and the term “juvenile” for cases where BD started prior to 16 years of age but the complete form of the disease manifested after this age.

Neurological involvement in BD was first described in adults in 1941 [55]. Some years later, histological findings were reported from the autopsy of a dermatological case [56]. The term “Neuro-Behçet syndrome” was suggested in 1954 by the Italian ophthalmologists Cavara and D’Ermo [3]. During the following decades, patients with BD have usually been labelled as having “neurological involvement”, as CNS involvement was considered one factor in the context of different clinical manifestations and not as a specific characterisation of the disease (i.e., NBD). A more precise correlation between neurological symptoms and anatomical lesions was made possible with progress in neuroimaging. MRI, which can be combined with angiography (MRA), represents the mainstay examination to assess the radiological patterns that distinguish the parenchymal form (more common in adult patients) from the non-parenchymal or vascular form [8, 57, 58]. Concerning the parenchymal involvement, MRI shows lesions mainly in the brainstem, basal ganglia, and white matter in adult patients [5860]. The most typical MRI findings appear as lesions with high signal intensity on T2-weighted sequences [58, 6062]. A specific study on MRI interpretation of the parenchymal form in children stated that NBD should be suspected in patients who have brainstem and/or diencephalic lesions that extend along the long tracts whether or not the lesions are associated with periventricular and subcortical lesions [38]. These lesions tend to resolve on subsequent imaging studies. MRI findings have been reported as normal or abnormal in primary progressive disease with silent neurological involvement [58, 62]. MRI evidence of brainstem atrophy is a well-defined feature for late NBD [58, 63, 64]. Concerning the non-parenchymal form, gadolinium-enhanced MRI and MRA have been used to confirm the diagnosis of CVST [65]. Compared with conventional MRI sequences, susceptibility-weighted imaging has proven to be particularly effective for detecting lesions [66]. Molecular imaging with positron emission tomography (PET) and SPECT may allow the characterisation of regional cerebral blood flow and metabolism. Similar to reports in adults, SPECT is very sensitive for detecting vascular brain involvement in paediatric patients with BD; it may support the clinical diagnosis, especially in children with negative findings on a brain structural examination, and may possibly reflect cortical diffuse low-grade inflammation better than MRI [34]. Hypoperfusion is observed mainly in the parietal lobes, basal ganglia, talami, and temporal cortex, including its mesial portion, whereas the cerebellum is the least common hypoperfused area [67]. Temporal hypoperfusion is found primarily in patients with seizures; hypoperfusion of deep grey nuclei is seen mainly in patients with different manifestations [34]. Some lesions on MRI, particularly white matter lesions, cannot be detected with SPECT, suggesting that MRI is more sensitive in this area [67]. SPECT brain perfusion imaging is performed more frequently than PET and uses different tracers [68] such as technetium-99 m hexamethylpropylene amine oxime (99mTc-HMPAO) [69], and more recently technetium-99 m ethyl cysteinate dimer (99mTc-ECD) [70, 71]. Of these two tracers, 99mTc-HMPAO is limited by radiochemical instability due to its rapid decomposition in vitro (it must be used within 30 minutes of preparation) and by delayed imaging (40 minutes after injection) [69]. Moreover, sensitivity with 99mTc-ECD results in superior images, which allow easier interpretation of brain structures [72]. Metabolic PET imaging with [18]F-fluordeoxyglucose can identify decreased cerebral glucose consumption at the parieto-occipital cortex and brainstem in neuro-BD [73]. Thus, neuroimaging is essential to substantiate the diagnosis of NBD. In specialized and equipped centres, the ideal diagnostic workup of NBD includes molecular imaging as a complementary modality to assess real involvement of the brain, particularly considering the recent availability of hybrid technology (PET/CT and SPECT/CT) leading to increased diagnostic accuracy and performance. Improvements in imaging after effective treatment have been documented for both MRI and SPECT [34, 38].

The demographics of paediatric patients with NBD (Table 1) confirm the well-known geographical distribution of the disease, with high prevalence in Western Asia and Southern Europe (particularly, France and Italy). However, reports have included all continents except for Oceania. This review found a prevalence of male cases, with a male/female ratio of 2.9:1. This value is definitely closer to that reported in series addressing the neurological involvement in BD independently of the age of appearance (i.e., adults and children) [3, 4, 8, 14, 50], than with reports focusing specifically on paediatric BD [2931, 49, 52]. Neurological involvement appears to be strongly related to male gender. Series specifically addressing the ocular involvement of BD in childhood showed a nearly two folds prevalence of males [13, 74]. The mean age at diagnosis is 11.8 years, with a median of 12 years. This means that a peak in neurological manifestations is observed around puberty, although the onset of the neurological disease may be observed after or before this age, including very early childhood.

Considering the differential diagnosis challenge and the problems related to classifying NBD, we decided to limit a detailed analysis of the neuro-ophthalmological findings to those cases with definitive radiological characterisation. More than 20% of these young patients complained of neuro-ophthalmological symptoms before the typical diagnostic elements were disclosed. This percentage rises to >35% considering the cases with a sole anamnestical report of oral and/or genital aphtae (not necessarily more than three episodes per year). This proportion is remarkably higher than that reported in other non-age-related NBD series, with no specification of whether the small number of cases with neurological onset were the youngest patients in the series [4, 43]. Family history was positive in 17% of the cases. This proportion is in accordance with what Koné-Pout and co-authors referred to in 1998 as “an unexpected finding”, commenting on the high rate of familial cases in their famous survey of BD in children compared with the rate commonly reported for adult patients [32]. This evidence was further supported by a segregation analysis after stratification of BD families into paediatric and non-paediatric groups, which detected a Mendelian autosomal recessive transmission only in paediatric families. In contrast, no evidence for Mendelian inheritance was observed in patients with BD and more typical age of onset criteria [75]. Three-fourths of subjects complained of headache, often associated with other alarming neurological findings such as nausea, vomiting, or papilledema (11 of 16 detailed cases). A higher prevalence of headache characterised the patients with cerebral vascular involvement. This symptom was evidently related to the presence of intracranial hypertension secondary to vascular complications, often consisting of thrombosis within large veins and occasionally arteries. No clear distinction between tension-type and migraine headaches was expressed among the non-vascular cases. However, the prevalence of headache in children with NBD cannot be clearly stated as being higher than that in the normal population. In large surveys on primary headaches among school children in Asian and European populations, the prevalence of recurrent episodes of headache ranged from 29.1% to 87.4% [7679].

Ocular alterations were described in 21/27 cases (78%). Optic nerve head involvement was the most frequently reported alteration (52%), chiefly in the form of papilledema. Primitive ocular involvement (i.e., excluding ocular findings secondary to neurological alterations such as papilledema, nystagmus, and extra-ocular muscle palsies) was reported in 12 cases (44%) as an inflammation of the posterior segment of the eye (posterior uveitis), with prevalence of retinal vasculitis (seven subjects). No cases had pure anterior uveitis, although iridocyclitis, with or without hypopyon, is considered a classic finding in BD [80]. Among the cases with a definitive radiological characterisation, the non-parenchymal form, in particular with CVST, was predominant. However, this evidence is influenced by a recent Turkish series; [14] excluding this series, the parenchymal and non-parenchymal forms were reported almost equally.

The prognosis was good in about 80% of cases who experienced recovery or significant improvement of neuro-ophthalmological alterations by the end of follow-up, even in cases of recurrent attacks. Nine patients (17%) had definitive visual and/or neurological sequelae. One patient presenting with a vascular form died. The rate of favourable prognosis was slightly worse (57%) in cases without radiological characterisation; this evidence is of uncertain interpretation. A possible explanation is that the lack of pathognomonic radiological features implied a delayed diagnosis and treatment. Improvement was always obtained with a slowly tapered immunosuppressive regimen, and the drugs used most often were systemic steroids, colchicine, and azathioprine, in decreasing order. The European League Against Rheumatism (EULAR) standardised operating procedures for the management of BD [8183]. There are no controlled data to guide the management of CNS involvement in BD. For parenchymal involvement agents to be tried may include corticosteroids, interferon α (INFα), azathioprine, cyclophosphamide, methotrexate, and anti-tumour necrosis factor drugs. For dural sinus thrombosis corticosteroids are recommended. Cyclosporine A, due to its potential neurotoxicity, should be avoided in patients with BD with CNS involvement, unless necessary for intraocular inflammation. Although the effectiveness of INFα in controlling even recalcitrant manifestations of BD is well demonstrated [84, 85], no patient in this review was treated with this drug, probably due to the young age. Any patient with BD and inflammatory eye disease affecting the posterior segment should be on a treatment regimen that includes azathioprine and systemic corticosteroids. Azathioprine is widely accepted as the initial agent for ocular involvement of BD. Corticosteroids rapidly suppress the inflammation but potential side effects including cataract and glaucoma cause concern. The systematic literature research considers about 20 randomized controlled trials (RCTs) on the management of patients with BD, but there are no studies relating to the management of gastrointestinal and neurological involvement. Moreover, questions related to treatment of early and pediatric form of the disease were not addressed by EULAR’s recommendations. Another problem that has not been adequately addressed in RCTs is whether anticoagulation is required for the venous thrombosis in BD.

In our experience, as well as in at least five cases reported in the literature (see Table 3), the non-parenchymal form began with binocular diplopia as predominant symptom. In these cases, diplopia was related to a peripheral ophthalmoplegia due to a “stretching” effect on the troncular pars of the sixth cranial nerve at the level of Dorello’s canal, secondary to the elevated intracranial pressure (third and fourth cranial nerve are rarely involved). However, sixth nerve palsy remains a poorly specific sign of increased intracranial pressure. Differential diagnosis should consider pathologies typically responsible for intracranial hypertension, in particular IIH or CVST due to causes other than primary vasculitis (e.g. otitis media with mastoiditis). In any case, neuroimaging is essential to support differential diagnosis of acute intracranial hypertension, focussing on exclusion of an expanding intracranial mass, CVST, IIH, or impending meningitis, with decreasing frequency.

In several cases of NBD, mostly non-parenchimal forms, early symptoms were consistent with those reported for IIH, i.e.: pulsatile headache (possibly precipitated by changes in posture), prolonged vomiting, pulsatile tinnitus, transient visual obscurations, blurred vision, and diplopia. IIH is frequently the cause of increased intracranial pressure and papilledema in young adults and, sometimes, in children. This syndrome has some characterising features, and obesity is one of the most significant [86, 87]. For this reason, the Body Mass Index is an easily achievable parameter able to orient differential diagnosis in a young patient presenting with intracranial hypertension. Also a previous antibiotic regimen should be carefully investigated in children; IIH may occur after a symptom-free period of weeks following the use of different categories of antibiotics for general infections (e.g. tetracycline, or nalidixic acid). However, to reach a definitive diagnosis of IIH the revised Dandy’s criteria must be satisfied, as follows: 1) elevated cerebrospinal fluid pressure with normal composition, as documented by lumbar puncture; 2) normal neurological examination except for papilledema and possibly sixth nerve palsy; 3) no evidence of hydrocephalus or a mass, structural, or vascular lesion on MRI or contrast-enhanced CT for typical patients, or on MRI and MRA for all others; and 4) no other cause of intracranial hypertension identified [88]. Funduscopic examination of the optic nerve head is strictly recommended in all cases of suspected or confirmed elevated intracranial pressure, in order to prevent severe visual alterations related to true papilledema [89]. From a theoretical point of view, papilledema may produce an irreversible visual loss just a few weeks after intracranial hypertension has been established. Actually, the amount of axonal loss in papilledema is related to the severity and the duration of the optic disc swelling, with severity and duration acting as independent variables.

In summary, we can conclude that increased intracranial pressure, headache, papilledema, and possibly diplopia owing to the involvement of the intracranial portion of the sixth nerve represent the prevalent clinical presentations of the vascular form of NBD. Physicians should not be tempted to diagnose IIH in the case of headache with papilloedema without careful exclusion of all differential diagnoses. In children these symptoms could be early manifestations of BD and the differential diagnosis often requires multidisciplinary expertise (i.e. paediatric, neurological, ophthalmological, and immunological). With a delayed diagnosis, it may not be possible to prevent optic atrophy even with a good control of other systemic symptoms. This review updates a previous database on the topic [90] to 1989 and may assist in the interpretation of results from upcoming large cohorts of patients who were followed longitudinally [91].


  1. 1.

    Behçet H: Über rezidivierende, aphtöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Derm Wschr. 1937, 105: 1152-1157.

    Google Scholar 

  2. 2.

    Criteria for Diagnosis of Behçet’s Disease. International Study Group for Behçet’s disease: Criteria for the diagnosis of Behçet’s disease. Lancet. 1990, 335: 1078-1080.

    Google Scholar 

  3. 3.

    Al-Araji A, Kidd DP: Neuro-Behçet’s disease: epidemiology, clinical characteristics and management. Lancet Neurol. 2009, 8: 192-204. 10.1016/S1474-4422(09)70015-8.

    PubMed  Article  Google Scholar 

  4. 4.

    Akman-Demir G, Serdaroglu P, Tasçi B, the Neuro-Behçet Study Group: Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain. 1999, 122: 2171-2178. 10.1093/brain/122.11.2171.

    PubMed  Article  Google Scholar 

  5. 5.

    Hirohata S, Issihi K, Oguchi H, et al: Cerebrospinal fluid interleukin-6 in progressive neuro-Behçet’s syndrome. Clin Immunol Immunopathol. 1997, 82: 12-17. 10.1006/clin.1996.4268.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Hirohata S, Kikuchi H: Behçet’s disease. Arthritis Res Ther. 2003, 5: 139-146.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  7. 7.

    Hirohata S: Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci. 2008, 267: 41-47. 10.1016/j.jns.2007.09.041.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Serdaroglu P: Behçet’s disease and the nervous system. J Neurol. 1998, 245: 197-205. 10.1007/s004150050205.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Siva A, Altintas A, Saip S: Behçet’s syndrome and the nervous system. Curr Opin Neurol. 2004, 17: 347-357. 10.1097/00019052-200406000-00017.

    PubMed  Article  Google Scholar 

  10. 10.

    Al-Araji A, Sharquie K, Al-Rawi Z: Prevalence and patterns of neurological involvement in Behçet's disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry. 2003, 74: 608-613. 10.1136/jnnp.74.5.608.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  11. 11.

    Ideguchi H, Suda A, Takeno M, et al: Neurological manifestations of Behçet’s disease in Japan: a study of 54 patients. J Neurol. 2010, 257: 1012-1020. 10.1007/s00415-010-5454-2.

    PubMed  Article  Google Scholar 

  12. 12.

    Koné-Paut I, Chabrol B, Riss JM, Mancini J, Raybaud C, Garnier JM: Neurologic onset of Behçet's disease: a diagnostic enigma in childhood. J Child Neurol. 1997, 12: 327-341. 10.1177/088307389701200508.

    Article  Google Scholar 

  13. 13.

    Citirik M, Berker N, Songur MS, Soykan E, Zilelioglu O: Ocular findings in childhood-onset Behçet disease. J AAPOS. 2009, 13: 391-395. 10.1016/j.jaapos.2009.04.016.

    PubMed  Article  Google Scholar 

  14. 14.

    Uluduz D, Kurtuncu M: Yapici et al. Clinical characteristics of pediatric-onset neuro- Behçet‘s disease. Neurology. 2011, 77: 1900-1905. 10.1212/WNL.0b013e318238edeb.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Mizushima Y: Recent research into Behçet’s disease in Japan. Int J Tissue React. 1988, 10: 59-65.

    CAS  PubMed  Google Scholar 

  16. 16.

    O'Duffy JD, Carney JA, Deodhar S: Behçet’s disease. Report of 10 cases, 3 with new manifestations. Ann Inter Med. 1971, 75: 561-570.

    Article  Google Scholar 

  17. 17.

    Rosenthal T, Bank H, Aladjem M, David R, Gafni J: Systemic amyloidosis in Behçet's disease. Ann Inter Med. 1975, 83: 220-223.

    CAS  Article  Google Scholar 

  18. 18.

    Chajek T, Fainaru M: Behçet’s disease. Report of 41 cases and review of the literature. Medicine (Baltimore). 1990, 54: 179-196.

    Article  Google Scholar 

  19. 19.

    Colvard DM, Robertson DM, O’Duffy D: The ocular manifestations of Behçet's disease. Arch Ophthalmol (Paris). 1977, 95: 1813-1817. 10.1001/archopht.1977.04450100115015.

    CAS  Article  Google Scholar 

  20. 20.

    Lebwohl O, Forde KA, Berdon WE, Morrison S, Challop R: Ulcerative esophagitis and colitis in a pediatric patient with Behçet's syndrome. Am J Gastroenterol. 1977, 68: 550-555.

    CAS  PubMed  Google Scholar 

  21. 21.

    Mundy TM, Miller JJ: Behçet's disease presenting as chronic aphthous stomatitis in a child. Pediatrics. 1978, 62: 205-208.

    CAS  PubMed  Google Scholar 

  22. 22.

    Leonard RCF, Thompson RB: Behçet's syndrome and neutropenia. Postgrad Med J. 1981, 57: 448-449. 10.1136/pgmj.57.669.448.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  23. 23.

    Vlymen WJ, Moskowiz PS: Roentgenographic manifestation of oesophageal and intestinal involvement in Behçet's disease in children. Pediatr Radiol. 1981, 10: 193-196. 10.1007/BF01001580.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Amman AJ, Johnson A, Fyfe GA, Leonards R, Wara DW, Cowan MJ: Behçet syndrome. J Pediatr. 1985, 107: 41-43. 10.1016/S0022-3476(85)80611-9.

    Article  Google Scholar 

  25. 25.

    Frayha RA, Afifi AK, Bergman RA, Nader S, Bahuth NBD: Neurogenic muscular atrophy in Behçet's disease. Clin Rheumatol. 1985, 4: 202-211. 10.1007/BF02032295.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Stern JM, Kesler SM: Raised intracranial pressure in a 16-year-old boy Report of a case of Behcet’s disease. South African Med J. 1989, 75: 243-244.

    CAS  Google Scholar 

  27. 27.

    Kerr JS, Roach ES, Sinal SH, McWhorter JM: Intracranial arterial aneurysms complicating Behçet's disease. J Child Neurol. 1989, 4: 147-149. 10.1177/088307388900400217.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Rakover Y, Adar H, Tal I, Lang Y, Kedar A: Behçet disease: long-term follow-up of three children and review of the literature. Pediatrics. 1989, 83: 986-992.

    CAS  PubMed  Google Scholar 

  29. 29.

    Pivetti-Pezzi P, Accorinti M, Abdulaziz MA, La Cava M, Torella M, Riso D: Behçet’s disease in children. Jpn J Ophthalmol. 1995, 39: 309-314.

    CAS  PubMed  Google Scholar 

  30. 30.

    Bahabri SA, Al-Mezyed A, Al-Balaa S, El-Ramahi L, Al-Dalaan A: Juvenile Behçet’s disease in Arab children. Clin Exper Rheumatol. 1996, 14: 331-335.

    CAS  Google Scholar 

  31. 31.

    Fujikama S, Suemitsu T: Behçet disease in children: a nationwide retrospective survey in Japan. Acta Paediatr Jpn. 1997, 39: 285-289. 10.1111/j.1442-200X.1997.tb03601.x.

    Article  Google Scholar 

  32. 32.

    Koné-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Özdogan H, et al: Clinical features of Behçet's disease in children: an international collaborative study of 86 cases. J Pediatr. 1998, 132: 721-725. 10.1016/S0022-3476(98)70368-3.

    PubMed  Article  Google Scholar 

  33. 33.

    Mitra S, Koul RL: Paediatric neuro-Behçet's disease presenting with optic nerve head swelling. Br J Ophthalmol. 1999, 83: 1096-10.1136/bjo.83.9.1096.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  34. 34.

    Vignola S, Nobili F, Picco P, Gattorno M, Buoncompagni A, Vitali P, et al: Brain perfusion SPECT in juvenile Neuro-Behçet's disease. J Nucl Med. 2001, 42: 1151-1157.

    CAS  PubMed  Google Scholar 

  35. 35.

    Alper G, Yilmaz Y, Ekinci G, Köse Ö: Cerebral vein thrombosis in Behçet's disease. Pediatr Neurol. 2001, 25: 332-335. 10.1016/S0887-8994(01)00314-9.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Budin C, Ranchin B, Glastre C, Fouilhoux A, Canterino I, David L: Neurological signs revealing a Behçet’s disease: two pediatric cases. Arch Pediatr. 2002, 9: 1160-1162. 10.1016/S0929-693X(02)00096-9.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Chaloupka K, Baglivo E, Hofer M, Chizzolini C, Delavelle J, Rossillion B, et al: Cerebral sinus thrombosis in Behçet disease: case report and review of the literature. Klin Mbl Augenheilkd. 2003, 220: 186-188. 10.1055/s-2003-38186.

    Article  Google Scholar 

  38. 38.

    Saltik S, Saip S, Kocer N, Siva A, Yalçinkaya C: MRI findings in pediatric neuro-Behçet’s disease. Neuropediatrics. 2004, 35: 190-193. 10.1055/s-2004-815826.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Allali F, Benomar A, Karim A, Lazrak N, Mohcine Z, El-Yahyaoui M, et al: Behçet’s disease in Moroccan children: a case report of 12 cases. Scand J Rheumatol. 2004, 33: 362-363. 10.1080/03009740410005980.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Can E, Kara B, Somer A, Keser M, Salman N, Yalçin I: Neuro-Behçet disease presenting as secondary pseudotumor syndrome: case report. Eur J Paediatr Neurol. 2006, 10: 97-99. 10.1016/j.ejpn.2006.02.003.

    PubMed  Article  Google Scholar 

  41. 41.

    Hatachi S, Nakazawa T, Morinobu A, Kasagi S, Kogata Y, Kageyama G, et al: A pediatric patient with neuro-Behçet's disease. Mod Rheumatol. 2006, 16: 321-323. 10.1007/s10165-006-0507-1.

    PubMed  Article  Google Scholar 

  42. 42.

    Kara B, Somer A, Piskin S, Aydinli N, Salman N, Yalçin I: Neuro-Behçet syndrome presenting as acute meningeal syndrome. J Infect. 2006, 52: e120-e123. 10.1016/j.jinf.2005.07.026.

    PubMed  Article  Google Scholar 

  43. 43.

    Joseph FG, Scolding NJ: Neuro-Behçet's disease in Caucasians: a study of 22 patients. Eur J Neurol. 2007, 14: 174-180. 10.1111/j.1468-1331.2006.01613.x.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Paniker JN, Vinayan KP, Ahsan Moosa NV, Elango EM, Kumar AA: Juvenile Behçet’s disease: highlighting neuropsychiatric manifestations and putative genetic mechanisms. Clin Neurol Neurosurg. 2007, 109: 436-438. 10.1016/j.clineuro.2007.01.009.

    Article  Google Scholar 

  45. 45.

    Atkinson M, Moore E, Altinok D, Acsadi G: Cerebral infarct in pediatric neuro-Behçet's disease. J Child Neurol. 2008, 23: 1331-1335. 10.1177/0883073808318199.

    PubMed  Article  Google Scholar 

  46. 46.

    Pipitone N, Olivieri I, Padula A, D’Angelo S, Nigro A, Zuccoli G, et al: Infliximab for the treatment of neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum. 2008, 59: 285-290. 10.1002/art.23345.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Robinson AB, Gallentine WB, Rabinovich CE: Pediatric Neuro-Behçet’s disease responsive to adalimumab. Pediatr Neurol. 2010, 43: 291-293. 10.1016/j.pediatrneurol.2010.04.021.

    PubMed  Article  Google Scholar 

  48. 48.

    Metreau-Vastel J, Mikaeloff Y, Tardieu M, Koné-Paut I, Tran TA: Neurological involvement in pediatric Behçet’s disease. Neuropediatrics. 2010, 41: 228-234. 10.1055/s-0030-1269909.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Atmaca L, Boyvat A, Yalçindağ FN, Atmaca-Sonmez P, Gurler A: Behçet disease in children. Ocul Immunol Inflamm. 2011, 19: 103-107. 10.3109/09273948.2011.555592.

    PubMed  Article  Google Scholar 

  50. 50.

    Yilmaz S, Serdaroglu G, Unver H, Akcay A, Gokben S, Tekgul H: Recurrent pseudotumor cerebri in childhood: a case of Neuro-Behçet disease complicated with thrombotic risk factors. J Child Neurol. 2011, 26: 881-884. 10.1177/0883073810391905.

    PubMed  Article  Google Scholar 

  51. 51.

    Krupa B, Cimaz R, Ozen S, Fischbach M, Cochat P, Koné-Paut I: Pediatric Behçet's disease and thrombosis. J Rheumatol. 2011, 38: 387-390. 10.3899/jrheum.100257.

    PubMed  Article  Google Scholar 

  52. 52.

    Konè-Paut I, Gorchakoff-Molinas A, Weschler B, Touitoi I: Paediatric Behçe’t disease in France. Ann Rheum Dis. 2002, 61: 655-656. 10.1136/ard.61.7.655.

    PubMed Central  PubMed  Article  Google Scholar 

  53. 53.

    O’Neill TW, Rigby AS, McHugh S, Silman AJ, Barnes C, on behalf of the International Study Group for Behçet’s Didease: Regional differences clinical manifestation of Behçet’s disease. Excepta Medica. Edited by: Weschler B, Godeau P. 1993, Amsterdam: Elsevier Science Publishers, 159-164.

    Google Scholar 

  54. 54.

    Koné-Paut I: Behçet’s disease: pediatric features. Ann Med Interne (Paris). 1999, 150: 571-575.

    Google Scholar 

  55. 55.

    Knapp P: Beitrag zur Symptomatologie und Therapie der rezidivierenden Hypopioniritis und der begleitenden aphtösen Schleimhauterkrankungen. Schweiz Med Wochenschr. 1941, 71: 1288-1290.

    Google Scholar 

  56. 56.

    Berlin C: Behçet’s syndrome with involvement of central nervous system. Arch Derm Syph (Chic). 1944, 49: 227-233. 10.1001/archderm.1944.01510100003001.

    Article  Google Scholar 

  57. 57.

    Jager HR, Albrecht T, Curati-Alasonatti WL, Williams EJ, Haskard DO: MRI in neuro-Behcet’s syndrome: comparison of conventional spin-echo and FLAIR pulse sequences. Neuroradiology. 1999, 41: 750-758. 10.1007/s002340050837.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Akman-Demir G, Bahar S, Coban O, Tasci B, Serdaroglu P: Cranial MRI in Behçet’s disease: 134 examinations of 98 patients. Neuroradiology. 2003, 45: 851-859. 10.1007/s00234-003-1102-1.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Kocer N, Islak C, Siva A, et al: CNS involvement in Neuro-Behçet’s syndrome: an MR study. Am J Neuroradiol. 1999, 20: 1015-1024.

    CAS  PubMed  Google Scholar 

  60. 60.

    Saadoun D, Wechsler B: Behçet’s disease. Orphanet J Rare Dis. 2012, 7: 20-10.1186/1750-1172-7-20.

    PubMed Central  PubMed  Article  Google Scholar 

  61. 61.

    Tali ET, Atilla S, Keskin T, Simonson T, Isik S, Yuh WT: MRI in neuro-Behçet’s disease. Neuroradiology. 1997, 39: 2-6. 10.1007/s002340050356.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Haghighi AB, Sarhadi S, Farahangiz S: MRI findings of neuro-Behçet’s disease. Clin Rheumatol. 2011, 30: 765-770. 10.1007/s10067-010-1650-9.

    Article  Google Scholar 

  63. 63.

    Coban O, Bahar S, Akman-Demir G, et al: Masked assessment of MRI findings: is it possible to differentiate neuro-Behçet’s disease from other central nervous system. Neuroradiology. 1999, 41: 255-260. 10.1007/s002340050742.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Gerber S, Biondi A, Dormont D, Wechsler B, Marsault C: Long term MRI follow-up of cerebral lesions in neuro-Behçet’s disease. Neuroradiology. 1996, 38: 761-768. 10.1007/s002340050343.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Danaci M, Akpolat T, Koyuncu M, Unal R, Belet U: The advantages of MRI and MRA for diagnosing Behcet’s disease and internal jugular vein thrombosis. Comput Med Imaging Graph. 2000, 24: 121-124. 10.1016/S0895-6111(99)00044-0.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Albayram S, Saip S, Hasiloglu ZI: Evaluation of parenchymal Neuro-Behcet disease by using susceptibility-weighted imaging. AJNR. 2011, 32: 1050-1055. 10.3174/ajnr.A2477.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Kao CH, Lan JL, ChangLai SP, Chieng PU: Technetium-99 m-HMPAO SPECT and MRI of brain in patients with neuro-Behcet’s syndrome. J Nucl Med. 1998, 39: 1707-1710.

    CAS  PubMed  Google Scholar 

  68. 68.

    Juni JE, Waxman AD, Devous MD: Procedure guideline for brain perfusion SPECT using technetium-99 m radiopharmaceuticals Society of Nuclear Medicine. J Nucl Med. 1998, 39: 923-926.

    CAS  PubMed  Google Scholar 

  69. 69.

    Neirinckx R, Canning L, Piper I: Technetium-99 m-HMPAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med. 1987, 28: 191-202.

    CAS  PubMed  Google Scholar 

  70. 70.

    Leveille J, Demonceau G, De Roo M: Characterization of Tc-99 m-L, L-ECD for brain perfusion. Part 2. Biodistribution and brain imaging in humans. J Nucl Med. 1989, 30: 1902-1910.

    CAS  PubMed  Google Scholar 

  71. 71.

    Walovitch RC, Cheesman EH, Maheu LJ, Hall KM: Studies of the retention mechanism of the brain perfusion imaging agent 99mTc-bicisate (99mTc-ECD). J Cereb Blood Flow Metab. 1994, 14: S4-S11.

    CAS  PubMed  Google Scholar 

  72. 72.

    Rieck H, Adelwohrer C, Lungenschmid K, Deisenhammer E: Discordance of technetium-99 m-HMPAO and technetium-99 m-ECD SPECT in herpes simple encephalitis. J Nucl Med. 1998, 39: 1501-1508.

    Google Scholar 

  73. 73.

    Weiner SM, Otte A, Schumacher M, et al: Neuro-Behcet’s syndrome in a patient not fulfilling criteria for Behcet’s disease: clinical features and value of brain imaging. Clin Rheumatol. 2000, 19: 231-234. 10.1007/s100670050164.

    CAS  PubMed  Article  Google Scholar 

  74. 74.

    Tugal-Tutkun I, Urgancioglu M: Childhood-onset uveitis in Behçet disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003, 136: 1114-1119. 10.1016/S0002-9394(03)00791-8.

    PubMed  Article  Google Scholar 

  75. 75.

    Molinari N, Koné-Paut I, Manna R, Demaille J, Daures JP, Touitou I: Identification of an autosomal recessive mode of inheritance in paediatric Behçe’t families by segregation analysis. Am J Med Genet A. 2003, 122A: 115-118. 10.1002/ajmg.a.20136.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Zwart JA, Dyb G, Holmen TL, Stovner LJ, Sand T: The prevalence of migraine and tension-type headaches among adolescent in Norway. The Nord-Trondelang Health Study (Head-HUNT-Youth), a large population-based epidemiological study. Cephalalgia. 2004, 24: 373-379. 10.1111/j.1468-2982.2004.00680.x.

    PubMed  Article  Google Scholar 

  77. 77.

    Fendrich K, Vennemann M, Pfaffenrath V, et al: Headache prevalence among adolescents-the German DMKG headache study. Cephalalgia. 2007, 27: 347-354. 10.1111/j.1468-2982.2007.01289.x.

    CAS  PubMed  Article  Google Scholar 

  78. 78.

    Visudtibhan A, Boonsopa C, Thampratankul L, et al: Headache in junior high school students: types and characteristics in Thai children. J Med Assoc Thai. 2010, 93: 550-557.

    PubMed  Google Scholar 

  79. 79.

    Rho YI, Chung HJ, Lee KH, et al: Prevalence and clinical characteristics of primary headaches among school children in South Korea: a nationwide survey. Headache. 2011, 19: 1-8.

    Google Scholar 

  80. 80.

    Zafirakis P, Foster CS: Adamatiades-Behçet disease. Diagnosis and Treatment of Uveitis. Edited by: Foster CS, Vitale AT. 2002, Philadelphia: W.B. Saunders Co, 632-652.

    Google Scholar 

  81. 81.

    Dougados M, Betteridge N, Burmester GR, et al: EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004, 63: 1172-1176. 10.1136/ard.2004.023697.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  82. 82.

    Hatemi G, Silvan A, Bang D, et al: EULAR Reccomandation for the management of Behçet disease. Ann Rheum Dis. 2008, 67: 1656-1662. 10.1136/ard.2007.080432.

    CAS  PubMed  Article  Google Scholar 

  83. 83.

    Hatemi G, Silvan A, Bang D, et al: Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009, 68: 1528-1534. 10.1136/ard.2008.087957.

    CAS  PubMed  Article  Google Scholar 

  84. 84.

    Alpsoy E, Durusoy C, Ylmaz E, et al: Interferon Alfa-2° in the treatment of Behçet disease. Arch Dermatol. 2002, 138: 467-471. 10.1001/archderm.138.4.467.

    CAS  PubMed  Google Scholar 

  85. 85.

    Siddique SS, Shah R, Suelves AM, Foster CS: Road to remission: a comprehensive review of the therapy in uveitis. Expert Opin Investig Drugs. 2011, 20: 1497-1515. 10.1517/13543784.2011.617741.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Kupersmith MJ, Gamill L, Turbin R, Peck V, Spiegel P, Wall M: Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology. 1998, 50: 1094-1098. 10.1212/WNL.50.4.1094.

    CAS  PubMed  Article  Google Scholar 

  87. 87.

    Carta A, Bertuzzi F, Cologno D, Giorgi C, Montanari E, Tedesco S: Idiopathic intracranial hypertension (pseudotumor cerebri): descriptive epidemiology, clinical features, and visual outcome in Parma, Italy, 1990 to 1999. Eur J Ophthalmol. 2004, 14: 48-54.

    CAS  PubMed  Google Scholar 

  88. 88.

    Friedman DI, Jacobson DM: Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002, 59: 1492-1495. 10.1212/01.WNL.0000029570.69134.1B.

    PubMed  Article  Google Scholar 

  89. 89.

    Carta A, Favilla S, Prato M, Bianchi-Marzoli S, Sadun AA, Mora P: Accuracy of funduscopy to identify true edemaversus pseudoedema of the optic disc. Invest Ophthalmol Vis Sci. 2012, 53: 1-6. 10.1167/iovs.11-8082.

    PubMed  Article  Google Scholar 

  90. 90.

    Lang BA, Laxer RM, Thorner P, GreeNBDerg M, Silverman ED: Pediatric onset of Behçet’s syndrome with myositis: case report and literature review illustrating unusual features. Arthritis Rheum. 1990, 33: 418-425. 10.1002/art.1780330317.

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Koné-Paut I, Darce-Bello M, Shahram F, et al: Registries in rheumatological and musculoskeletal condition. Paediatric Behçet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011, 50: 184-188. 10.1093/rheumatology/keq324.

    Article  Google Scholar 

Download references


The authors thank Laura Zavota from the Paediatric Division of Parma Hospital (Italy), and Nicoletta Masera from the Pediatric Clinic of San Gerardo Hospital in Monza (Italy) for their fundamental assistance in the management of the cases come to our observation.

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see:

Author information



Corresponding author

Correspondence to Paolo Mora.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

PM analyzed data and wrote the manuscript; CM selected source literature; JGO conceived and supervised the study; PR helped in managing cases from personal experience; LR was responsible for radiological examination and discussion; AC was responsible for neuro-ophthalmolgical examination and discussion. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Mora, P., Menozzi, C., Orsoni, J.G. et al. Neuro-Behçet’s disease in childhood: A focus on the neuro-ophthalmological features. Orphanet J Rare Dis 8, 18 (2013).

Download citation


  • Magnetic Resonance Angiography
  • Intracranial Hypertension
  • Central Nervous System Involvement
  • Optic Atrophy
  • Papilledema